Celprogen Introduces Stem Cells In Syringes For In Vivo Applications
Main Category: Stem Cell ResearchArticle Date: 19 Sep 2008 - 7:00 PDT
| Patient / Public: | ![]() |
5 (1 votes) |
| Healthcare Prof: | ![]() |
Celprogen Inc., a Global leader in the Stem Cell Research and Therapeutics industry for development of stem cell technologies in regenerative medicine, announced that they have successfully validated shipment of embryonic and adult stem cells at room temperature within United States research facilities for in vivo applications. These Stems including progenitor cells were derived from the following species mouse, rat and human.
Celprogen's stem cells and progenitor cells in the syringes are available for basic science research and drug discovery. The stem cells validated in syringe shipment are as follows: Hepatocytes, Neuronal, Pancreatic, Gastric, Cardiomyocytes, Colon, Lung and Keratinocytes. These stem cells in their syringes are able to maintain their stem-ness and are able to engraft at their organ specific sites once injected within 3 to 5 days from the date shipped. Celprogen has successfully shipped stem cells globally at room temperature in Tissue culture flasks to Asia, Europe and United Kingdom.
Celprogen provides Stem Cell Tissue culture system which includes cells, pre-coated flasks with extracellular matrix and Medium for growth and proliferation of these cells. The stem cell culture system includes stem cell differentiation, expansion and maintaining stem cells in their undifferentiated stage.
About Celprogen Inc.
Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing proprietary portfolio of unique cancer therapeutics products and life science research tools that includes stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell products to serve our global community.
Celprogen Inc.
Visit our stem cell research section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/122187.php>
APA
http://www.medicalnewstoday.com/releases/122187.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





